# A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics

> **NCT03754244** · PHASE1 · TERMINATED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 1 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** TQB3456

## Key facts

- **NCT ID:** NCT03754244
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-24
- **Primary completion:** 2022-02-28
- **Final completion:** 2022-02-28
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The enrolment task cannot be gotten within the planned time.It mainly includes patients with non-small cell lung cancer failed in standard treatment,with a short survival period.It is hard to obtain observational endpoints for bone-related events.
- **Last updated:** 2022-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03754244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03754244, "A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03754244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*